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ABSTRACT The toothless (tl) osteopetrotic mutation in the rat affects an osteoblast-derived factor
that is required for normal osteoclast differentiation. Although the genetic locus remains unknown,
the phenotypic impact of the tl mutation on multiple systems has been well characterized. Some of
its actions are similar to tumor necrosis factor superfamily member 11 (TNFSF11; also called TRANCE,
RANKL, ODF and OPGL) null mice. TNFSF11 is a recently described member of the tumor necrosis
factor superfamily which, when expressed by activated T cells, enhances the survival of antigen-
presenting dendritic cells, and when expressed by osteoblasts, promotes the differentiation and
activation of osteoclasts. The skeletal similarities between tl rats and TNFSF11(-/-) mice include 1)
profound osteoclastopenia (TNFSF11-null mice, 0% and tl rats 0-1% of normal); 2) persistent, non-
resolving osteopetrosis that results from 3) a defect not in the osteoclast lineage itself, but in an
osteoblast-derived, osteoclastogenic signal; and 4) a severe chondrodysplasia of the growth plates of
long bones not seen in other osteopetrotic mutations. The latter includes thickening of the growth
plate with age, disorganization of chondrocyte columns, and disturbances of chondrocyte maturation.
These striking similarities prompted us to undertake studies to rule in or out a TNFSF11 mutation in
the tl rat. We looked for expression of TNFSF11 mRNA in tl long bones and found it to be over-expressed
and of the correct size. We also tested TNFSF11 protein function in the tl rat. This was shown to be
normal by flow cytometry experiments in which activated, spleen-derived T-cells from tl rats exhibited
normal receptor binding competence, as measured by a recombinant receptor assay. We also found
that tl rats develop histologically normal mesenteric and peripheral lymph nodes, which are absent
from TNFSF11-null mice. Next, we found that injections of recombinant TNFSF11, which restores bone
resorption in null mice, had no therapeutic effect in tl rats. Finally, gene mapping studies using co-
segregation of polymorphic markers excluded the chromosomal region containing the TNFSF11 gene
as harboring the mutation responsible for the tl phenotype. We conclude that, despite substantial
phenotypic similarities to TNFSF11 (-/-) mice, the tl rat mutation is not in the TNFSF11 locus, and that
its identification must await the results of further studies.
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Introduction
Osteopetrosis, or marble bone disease, is an inherited, patho-
logical increase in bone mass that results from impaired bone
resorption by osteoclasts. Depending upon the mutated gene,
osteopetrotic phenotypes vary widely in severity, in age of onset
(or, in some cases, of spontaneous recovery), and in the extent to
which tissues and organs other than bone are affected (Popoff and
Marks, 1995). While most known mutations impact genes ex-
pressed by the osteoclasts or their progenitors, two known factors
expressed by osteoblasts are required to induce normal osteoclast
formation and activation, colony stimulating factor-1 (CSF-1 or M-
CSF; Yoshida et al., 1990) and the tumor necrosis factor superfam-
Abbreviations used in this paper: CSF-1, colony stimulating factor 1, also known
as m-CSF; RT-PCR, reverse transcription polymerase chain reaction; nlm,
normal littermate; tl, toothless osteopetrotic mutation; TNFRSF11A, tumor
necrosis factor receptor superfamily member 11A, also known as TRANCE
receptor and RANK; TNFSF11, tumor necrosis factor superfamily member 11
–also known as TRANCE, RANKL, ODF and OPGL; TRAP, tartrate-resistant
acid phosphatase.
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ily member TNFSF11 [(Kim et al., 2000; Kong et al., 1999); see
Locksley et al., 2001 for the most recent standardized nomencla-
ture for the TNF and TNF receptor superfamilies)] which has been
named, in chronological order, TRANCE (Wong et al., 1997),
RANKL (Anderson et al., 1997), ODF (Yasuda et al., 1998) and
OPGL (Kong et al., 1999)).
The toothless (tl) mutation in the rat produces severe osteo-
petrosis that is inherited in an autosomal, recessive manner
(Cotton and Gaines, 1974). Unlike many other osteopetrotic muta-
tions, the tl rat is not cured by hematopoietic stem cell transplan-
tation from its normal littermates (Marks, 1977), nor are tl-derived
osteoblasts capable of activating co-cultured normal osteoclasts
(Hermey et al., 1996; Sundquist et al., 1995). This means that the
defective gene is not a product of the osteoclast/monocyte/mac-
rophage lineage, but rather is an osteoblast-expressed factor. tl
rats have profound osteoclastopenia which contrasts, for example,
with the incisor absent (ia) mutation in which osteoclasts are
present at 2-3 times the normal numbers, but are small and non-
functional (Odgren and Marks, 1998). tl rats are also affected by
severe chondrodystrophy of the growth plate, with thickening of the
central area over time, disorganized chondrocyte columns, and
failure of growth cartilage to mineralize (Odgren et al., 1999;
Seifert, 1996).
We noted phenotypic manifestations of the tl mutation that bore
striking similarities to TNFSF11-null mice. First, TNFSF11 is pro-
duced in the skeleton by osteoblasts. Second, TNFSF11-null mice
have severe osteopetrosis that does not resolve with age. Third,
null mice have a profound deficiency of osteoclasts, with none
found in osteoclast-specific histologic staining of bone sections
(Kim et al., 2000; Kong et al., 1999). Finally, the growth plates of null
mice are dystrophic, a feature not seen in most other osteopetrotic
mutations. Chondrocytes are disorganized, with central thickening
of the growth plates and highly abnormal differentiation progres-
sion (Kim et al., 2000), much as is seen in the tl rat (Odgren et al.,
1999; Seifert, 1996). These observations led us to undertake
investigations to test the hypothesis that the tl rat is a loss-of-
function mutation in the TNFSF11 gene.
Results
Figure 1 shows comparative histology of dystrophic growth
plates of the tl rat and TNFSF11-null mice at 4 weeks of age. These
images of the central region of the proximal tibial growth plates
reveal phenotypic characteristics that motivated the present study.
Note the marked increase in thickness of both mutants compared
to their normal counterparts. Both mutations show failure to form
columns, mis-orientation of groups of cells, and failure to exhibit the
normal chondrocyte differentiation zones. The proliferating zone is
greatly increased in thickness in both mutants, with persistence of
small cells and isogenous groups typical of proliferating
chondrocytes well beyond the normal depth. Hypertrophic cells do
not reach their fully differentiated appearance in either of these
mutations, although near-complete hypertrophy is seen more
frequently in the TNFSF11-null mouse. Both mutations show areas
of growth cartilage that are devoid of cells, suggesting either
chondrocyte death or hypersecretion of cartilage matrix, or both.
The chondro-osseous junctions on the metaphyseal side of the
growth plates are also highly abnormal, and lack the thin, trans-
Fig. 1. Similar chondrodysplasias in tl rat and TNFSF11 -/- mice. One
of several phenotypic similarities is seen in proximal tibial growth plates of
4-week-old animals, with abnormal thickening of growth plates, disorga-
nized chondrocyte columns, and failure to form normal proliferating (P) or
hypertrophic (H) zones. (Left panels) Rat normal littermate (nlm) and tl
mutant (tl). (Right panels) Mouse normal littermate (nlm) and TNFSF11
knockout (ko). Both mutations also show areas of hypocellularity (aster-
isks), and lack thin transverse septae at the chondroosseous junction
(arrowheads in normals). Of the known osteopetrotic mutations, only
genes in the TNFSF11 osteoclast differentiation pathway have been
shown to produce this growth plate phenotype. (2 µm Epon sections,
toluidine blue stained.
Fig. 2. Northern blot for TNFSF11 mRNA. 20
µg of total RNA from long bones of 2-week-old
normal (n) and tl rats (tl) was loaded per lane,
and the blot probed with rat TNFSF11 cDNA.
At this loading, normal bone TNFSF11 mRNA
levels is at the detection threshold, while the tl
bone expressed higher levels of message.
Quantitation of signal showed roughly 8-fold
up-regulation in the mutant bone. Comparison
to rRNA gave an mRNA size of 2.1 kb, in good
agreement with the 2.2 kb full-length mouse
sequence.
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verse septae between columns of hypertrophic cells that form the
locus of normal vascular invasion and conversion to bone. An
ultrastructural analysis of these two phenotypes is in progress.
We examined expression in long bones of TNFSF11 mRNA by
Northern blot, and the results are shown in Fig. 2. An 808 base-pair
rat TNFSF11 cDNA (Gen Bank Accession # AF425669) was
obtained by degenerate oligo-nucleotide RT-PCR of normal rat
bone RNA that corresponds to bases 932-1740 of the mouse
cDNA (accession # AF013170), comprising the distal end of the
coding region and the proximal 3’UTR. There is 91% similarity
between rat and mouse in this region, with a 42 nucleotide gap from
bases 1361-1403 of the mouse sequence. This cDNA was used to
probe total RNA from long bones of tl rats and their normal
littermates, and a single band of roughly 2.1 kb was detected, in
good agreement with the 2.2 kb full-length mouse TNFSF11 cDNA
(Wong et al., 1997). Interestingly, the normal rat mRNA was barely
detectable at the loading used (20 µg of total long bone RNA per
lane), while the tl long bones had about 8-fold higher levels when
quantitated by phospho-imaging. This does not rule out a minor
mutation in TNFSF11 in the tl rat, but it does demonstrate that there
is neither a large rearrangement nor an inability to express the
TNFSF11 mRNA.
To test whether there might be a functional defect in the
TNFSF11 protein in the tl rat, we performed flow cytometric
analysis of spleen-derived activated T-cells. The cells were first
exposed to concanavalin A and IL-2 for 4 days to stimulate
TNFSF11 expression and then probed with recombinant mouse
TNFSF11 receptor fused to human IgG heavy chain, and labeled
with fluorescent anti-human IgG (Josien et al., 1999). As seen in
Fig. 3A, tl splenocytes bind the receptor construct in a manner
indistinguishable from their normal littermates. This result implies
that the TNFSF11 protein in tl rats is fully able to bind its receptor,
and therefore should participate normally in TNFSF11-mediated
signaling.
Further confirmation of normal TNFSF11 activity in the tl rat is
found in the lymphatic system, and is shown in Fig. 4. TNFSF11-
null mice have no peripheral or mesenteric lymph nodes (Kim et al.,
2000; Kong et al., 1999), whereas dissection of tl rats revealed well-
developed mesenteric lymph nodes as well as peripheral nodes.
Histological sections of mesenteric and peripheral (inguinal, sub-
mandibular, and paratracheal) lymph nodes from the tl rat are
normal, with dense populations of lymphocytes and normal-ap-
Fig. 3. Flow cytometry reveals functional TNFSF11 expressed by tl
splenocytes. Spleen cells were stimulated with Concanavalin A and IL-2
for 4 days, probed with hIgG (control, dotted line) or a chimeric protein
consisting of TNFSF11 receptor (TRANCE receptor/RANK) fused to human
IgG Fc chain (solid line), incubated with PE-conjugated goat anti-hIgG
F(ab’)
2
 and binding was analyzed by FACS. No significant difference was
seen between the receptors of  tl rats and those of their normal littermates.
Three separate experiments gave similar results.
Fig. 4. Normal lymph nodes in tl rats. Dissections of the abdominal cavity
(A,B) reveal well-developed mesenteric lymph nodes (arrows) in (A)
normal (n) and (B)mutant (tl) rats. Histological sections show that inguinal
lymph nodes from tl rats at (C) low and (D) higher magnification are well-
developed, with numerous lymphocytes and normal histological appear-
ance. p, paracortex; c, capsule. Arrow in D indicates sinus in dense region
of lymphocytes (3 µm glycol methacrylate section stained with H&E; bar,
150 µm in right panel; 600 µm in left panel).
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pearing stroma and lymphatic ducts. Figure 4 shows cross-sec-
tions of inguinal nodes. Similar results were seen in mesenteric and
other peripheral nodes (data not shown).
Next, we investigated the effect of treating tl rats with recombi-
nant TNFSF11. Recombinant TNFSF11 (human OPGL, kindly
provided by C. Dunstan, Amgen, Inc., Thousand Oaks, CA) was
injected subcutaneously into tl rats at 0.1 or 1 mg/kg of body weight
every other day for the first 10 post-natal days. X-rays of the treated
animals revealed no improvement in their osteopetrotic skeletons
(Fig. 5), nor was there any increase in osteoclasts seen in TRAP-
stained histological sections of long bones from the treated animals
(Fig. 6). Doses of 1 mg/kg rapidly induced osteoclast formation and
bone resorption in TNFSF11-null mice, with visible improvement in
X-rays (data not shown) and large numbers of osteoclasts in long
bones (Fig. 6). Treatment of normal littermates of tl rats with 2 mg/
kg every other day for a week caused an increase in metaphyseal
osteoclasts and fragility of bones, thus confirming the biological
activity of recombinant human TNFSF11 in the rat (not shown).
As the evidence against a TNFSF11 mutation accumulated in
the studies described above, we undertook genetic studies to
confirm this interpretation. The TNFSF11 gene position has not
been directly determined in the rat; nevertheless, it has been
mapped in both mouse and human, so its location can be inferred
from homology between chromosome regions. In both human and
mouse, the TNFSF11 gene is close to the ELF1 gene, on chromo-
somes 13 and 14, respectively, while in the rat it resides on
chromosome 15q. From this region, microsatellite markers were
selected for PCR-based segregation analysis as shown in Fig. 7.
We outcrossed the tl strain with brown Norway rats, yielding
heterozygous F1 rats. These F1’s in turn yielded 11 F2 rats having
the tl phenotype whose DNA was analyzed for co-segregation of
chromosome 15 markers with the mutation. The results in Fig. 7
show that the TNFSF11-containing region of chromosome 15 and
the tl mutation are not linked.
Discussion
The balance between bone formation and bone resorption that
is required for normal skeletal and mineral homeostasis, referred
to by bone biologists as “coupling,” requires both systemic and
local factors. The discovery of two osteoblast-derived signaling
molecules, CSF-1 and TNFSF11, that are required for normal
osteoclast ontogeny and activation represents a great advance in
understanding the molecular mechanisms underlying coupling.
Interestingly, the phenotype of a naturally-occurring CSF-1-null
mutation, the osteopetrosis (op) mouse (Yoshida et al., 1990), is
quite distinct from TNFSF11(-/-) mutants. Where TNFSF11-null
mice have no osteoclasts (Kim et al., 2000; Kong et al., 1999), the
op mouse does have them, although their numbers are low. The op
mouse also recovers spontaneously over the first few postnatal
months while the TNFSF11-null mouse does not, and there are no
growth plate abnormalities in the op mouse of the sort shown in Fig.
1. The spontaneous recovery of the op mouse suggests the
existence of an overlapping or redundant cytokine pathway that
can, with time, compensate for the missing CSF-1 in promoting
osteoclast differentiation in mice. This is not the case with TNFSF11-
null mice nor with tl rats, neither of which show improvement over
time.
The discovery of TNFSF11 and the parallels between the tl rat
skeletal phenotype and that of TNFSF11-null mice led us to
hypothesize that the tl rat may be a naturally-occurring TNFSF11
mutation in the rat. From the data presented in this report, we
conclude that this is not the case. First, the tl rat expresses
TNFSF11 mRNA in its long bones, and the message is the correct
size (Fig. 2). Second, tl rats develop histologically normal mesen-
teric and peripheral lymph nodes (Fig. 4). Third, the TNFSF11
protein expressed by mitogen-activated tl splenic T-cells is ca-
pable of binding to receptor (Fig. 3). Fourth, the tl rat is refractory
to injections of recombinant human TNFSF11 sufficient to induce
fully functional osteoclasts in knockout mice (Figs. 5 and 6).
Finally, segregation analysis of microsatellite markers flanking
the TNFSF11 gene enabled us to exclude the primary involve-
ment of this gene (Fig. 7).
Although one expects similar phenotypes in knockout mice for
genes that lie downstream in the TNFSF11 signal transduction
Fig. 5. Treatment of tl rats with recombinant TNFSF11shows no
radiologic improvement. X-rays of normal (n), tl, and TNFSF11-treated tl
(tl+) rats (1 mg/kg dose) at 10 days post-partum. Normal femur (f) and iliac
crest (ic) are seen in the left panel, with radiolucent marrow spaces, while
in both the untreated and treated mutants, there is severe osteopetrosis
and no radiological evidence of bone resorption.
Fig. 6. TNFSF11 does not induce osteoclast
formation in tl rats. TRAP staining (red) shows
abundant osteoclasts in 10-day-old normal (n)
rat tibia, especially among the metaphyseal
trabeculae (t) and the cortical region (c). No
TRAP-positive cells are seen in tl rats treated for
10 days with 1 mg/kg of recombinant TNFSF11
(tl+), while the same regimen induced osteo-
clast formation and activation in TNFSF11-(-/-)
mice (ko+). 3 µm glycol methacrylate tibia sec-
tions. gp indicates growth plate, for orientation.
Original magnification 20 X.
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pathway, for example its receptor (TNFRSF11A/TRANCE recep-
tor/RANK) (Li et al., 2000), or its intracellular, receptor-associated
factor TRAF6 (Lomaga et al., 1999), these molecules are pro-
duced by and act within the ostoeclast precursors themselves. The
tl mutation affects an osteoblast-expressed factor, i.e., tl rats are
not cured by transplants of normal osteoclast precursor cells
(Marks, 1977), nor can tl osteoblasts support the activation of
normal osteoclasts in co-culture systems (Hermey et al., 1996;
Sundquist et al., 1995). Together, these findings demonstrate that
the tl mutation is not a defect on the osteoclast side of normal
osteoblast-osteoclast communication.
The question then arises, what gene is responsible for the tl rat
phenotype? In addition to TNFSF11, the only other osteoblast-
derived, osteoclastogenic factor currently known is CSF-1. While
CSF-1 injections do restore some osteoclast populations in the tl
rat, there is no improvement in either the growth plates or long
bone growth when tl rats are treated with CSF-1 from birth through
six weeks (Odgren et al., 1999), nor is there any spontaneous
phenotypic improvement seen in tl rats over time as there is in the
op mouse. The gradual recovery of bone resorption in the op
mouse, in which a frame-shift mutation in the twelfth codon
abrogates CSF-1 function (Yoshida et al., 1990), suggests some
overlapping, compensatory pathway in cytokine-mediated osteo-
clast differentiation. These observations, combined with the present
data that eliminate TNFSF11 as the site of the tl mutation, raise two
possibilities. On the one hand, if the tl mutation actually is in the
CSF-1 gene, then one must be prepared to account for the widely
different phenotypic consequences in the op mouse versus the tl
Fig. 7. (A) Chromosomal localization of the rat TNFSF11
gene and (B) exclusion of the involvement of the
TNFSF11 gene by segregation analysis. (A) No precise
localization of the rat TNFSF11 gene is currently available,
but it can be deduced from comparative mapping. Both in
human and mouse, the TNFSF11 gene has been localized
close to the ELF1 gene, respectively on chromosomes 13
and 14. These chromosomal regions are syntenic with rat
chromosome 15, which contains the rat ELF1 gene, spe-
cifically within the proximal part of 15q. A set of microsatallite
markers spread over this region was selected for analysis.
(B)The inbred tl rat strain was crossed to the inbred BnSsN
strain. The black bars indicate the BnSsN haplotype and the
white indicate the tl haplotype. For informative microsatellite
markers selected from the region of chromosome 15,
heterozygosity is obtained in the F1 generation. Eleven tl/
tl animals resulting from intercrosses between F1 animals
were analyzed (F2, homozygous for the mutation), and the
patterns of inheritance and the number of animals are
indicated (3x, etc.). None of the selected markers were
found to cosegregate with the tl phenotype in all the F2
mutants, indicating that this region does not harbor the
disease-containing mutation.
rat. On the other hand, there may be a third, osteoblast-derived,
osteoclastogenic factor that is mutated in the tl rat. Molecular
genetic mapping experiments currently underway will help resolve
this important question.
Materials and Methods
All animal procedures were in accordance with the Guide for the Care
and Use of Laboratory Animals published by the National Institutes of
Health and were approved by the Institutional Animal Care and Use
Committee of the University of Massachusetts Medical School. Mutant (t/
tl) rats and their normal (+/?) littermates were obtained from inbred colonies
maintained for over twenty years at the University of Massachusetts
Medical School. Outbreeding of animals of tl stock was done by crossing
mutant males (genotype tl/tl; the trait is inherited in a Medelian recessive
manner) with females of inbred Brown Norway stock (BnSsN; Harlan
Sprague Dawley, Indianapolis, Indiana) to obtain F1 heterozygotes. Inter-
crosses of F1 yielded F2 animals for segregation analyses. The generation
of TNFSF11(-/-) mice was previously described (Kim et al., 2000). Colonies
of both the rat and mouse strains were maintained under specific-patho-
gen-free conditions. Mutants were distinguished from normals by neonatal
radiography as described (Schneider et al., 1979). In some experiments, tl
rats, normal littermates, and TNFSF11-null mice were treated with recom-
binant TNFSF11 (human OPGL, kindly provided by Dr. Colin Dunstan,
Amgen, Inc., Thousand Oaks CA). Based on the observations that doses
of 0.1 mg/kg, 1 mg/kg, and 2 mg/kg provide, respectively, minimal,
profound, and fatal hypercalcemia by 3-4 days in normal mice due to
increased bone resorption (Dr. Colin Dunstan, personal communication),
we used the following doses in the present study. Mutant rats and null mice
were treated with 0.1 or 1 mg/kg body weight, and normal rats received 2
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mg/kg, diluted in PBS. The higher dose for normal rats was to verify biologic
activity of the recombinant human protein in the rat. Treatment was by
subcutaneous injection every other day for 10 days. Control animals
received just PBS.
Histology
Dissected bones were stripped of extraneous tissue, fixed overnight in
cold 2.5% glutaraldehyde (Polysciences, Warrington PA) and 0.7% ruthe-
nium hexaamine trichloride (Polysciences) in 0.1 M sodium cacodylate and
post-fixed for 1-2 hours in 1% osmium tetroxide (Polysciences) in cacody-
late (Eggli et al., 1985; Eggli et al., 1988), demineralized in EDTA (10%
Na2EDTA in Tris-HCl, pH 8.0), and embedded in Epon (Polysciences). 2
µm sections were stained with 1% toluidine blue in 1% sodium borate. For
histological examination of lymph nodes and for tartrate-resistant acid
phosphatase (TRAP) histochemistry staining of osteoclasts, fixation was
done overnight in cold 2.5% glutaraldehyde in 0.1 M sodium cacodylate.
Bones were demineralized in EDTA and embedded in glycol methacrylate,
and 3 µm sections were stained by enzyme histochemistry for TRAP as
described (Lindunger et al., 1990). Glycol methacrylate-embedded lymph
node sections were stained with hematoxylin and eosin.
RNA analysis
Northern blots were done according to standard methods (Odgren et al.,
1996). RNA was isolated from frozen tibiae and femora by pulverization
followed by homogenization in Trizol (Life Technologies, Bethesda, MD), and
purified as recommended by the manufacturer. 20 µg of total RNA from 4-
week-old tl rats and their normal littermates was loaded per lane, probed with
32P-labeld probe (HighPrime kit, Roche, Indianapolis, IN), and scanned with
a Molecular Dynamics Storm phospho-imager. The probe was an 808 base-
pair cDNA for rat TNFSF11 obtained by RT-PCR from rat bone RNA
(GenBank Accession # AF425669). The sequence aligns with bases 932-
1740 of the mouse TNFSF11 sequence (GenBank accession # AF013170),
with 91% identity and one 42 bp gap from base 1361-1403 in the mouse
sequence.
FACS
Flow cytometry was carried out as described (Josien et al., 1999). Briefly,
total cells were harvested from spleens of 5-week-old tl rats and normal
littermates, and 5 X 106 cells were plated on 24-well culture plates in the
absence or presence of concanavalin A (5 ug/ml) and IL-2 (10 unit/ml) for 4
days. The expression of TRANCE on activated T cells was examined using
either baculovirus-expressed, affinity purified fusion protein of mouse TRANCE
receptor (TNFSFR11; RANK) fused to human IgG1 heavy chain or hIgG1
(control) at 5 ug/ml, followed by phycoerythrin (PE)-conjugated goat anti-
hIgG (Fc-specific) F(ab’)2 fragment (Caltag, Burlingame, CA).
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